Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ridinilazole (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Ri-CoDIFy; Ri-CoDIFy 2
  • Sponsors Summit Therapeutics

Most Recent Events

  • 14 Jul 2026 According to a Summit Therapeutics media release, results from this trial published in the journal Clinical Infectious Diseases.
  • 09 Nov 2022 According to a Summit Therapeutics media release, as of 30 September 2022, the company received non-dilutive funding of $0.8 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in support of the Companys Ri-CoDIFy clinical trials.
  • 20 Oct 2022 According to a Summit Therapeutics media release, results from this trial were presented at the IDWeek 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top